Enzymaster buys China facility
German enzyme catalysts maker has acquired Fujian Sanming Minhe Pharmaceutical Technology in order to meet the growing demand for biocatalysts in multiple industries. 40% of Sanming Minhe’s capacity will be dedicated to manufacturing products using Enzymaster technology, increasing Enzymaster’s global capacity by 50% to 600 tonnes/year of enzymes.
“The added capacity expands our ability to serve our clients worldwide. However, the extremely experienced management team with high levels of expertise was the most attractive to us,” said Michael Lv, president of Enzymaster. Dr Daofei Huang will henceforth serve as managing director of Sanming Minhe.
Sanming Minhe’s plant opened just a year ago and is located in western Fujian province close to an approved industrial park and the coast for ready access to shipping ports. It was already using equipment compatible with Enzymaster’s existing Chinese facility in Ningbo.
The site will become the primary manufacturing facility for pharmaceutical intermediates and additional compounds in Enzymaster’s pipeline. Its facilities include a kilo-scale technology development centre, plus both pilot- and commercial-scale production capacity.